Metabolic syndrome and cerebrovascular disease: Evidence in their treatment;Síndrome metabólico y enfermedad vascular cerebral: Evidencias en su tratamiento

Revista de Neurologia

Volumn 48, Issue 5, 2009, Pages 255-260

  Rodriguez Ku R J ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Centro Dermatológico de Yucatán   (Mexico)

Author keywords

Dyslipidaemia; Elevated fast glucose; Hypertension; Metabolic syndrome; Obesity; Stroke

Indexed keywords

BRAIN ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; REVIEW; RISK FACTOR; WEIGHT REDUCTION; DIABETES MELLITUS; PATHOPHYSIOLOGY;

CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 63449138124     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4805.2008365     Document Type: Review

References (74)

1. Sacco RL. The William Feinberg Lecture 2006: shifting the paradigm from stroke to global vascular risk estimation. Stroke 2007; 38: 1980-7.
2. Gil de Castro R, Gil-Núñez AC. Factores de riesgo del ictus isquémico. Rev Neurol 2000; 31: 314-23.
3. Gorelick PB. Stroke prevention therapy beyond antithrombotics; unifying mechanisms in ischemic stroke pathogenesis and implications for therapy; an invited review. Stroke 2002; 33: 862-75.
4. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laasko M, Kuusisto J. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly Finns. Stroke 2008; 39: 1078-83.
5. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 285: 2486-97.
6. Boden-Albala B, Sacco R, Lee HS, Grahame-Clarke C, Rundek T, MD, Elkind M, et al. Metabolic syndrome and ischemic stroke risk. Northern Manhattan Study. Stroke 2008; 39: 30-5.
7. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel (ATP). Third report of the NCEP-ATP. JAMA 2001; 285: 2486-752.
8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/Nation Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-52.
9. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-4.
10. Chen HJ, Bai CH, Yeh WT, Chiu HC. Influence of metabolic syndrome and general obesity on the risk of stroke. Stroke 2006; 37: 1060-4.
11. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 2008; 39: 1607-9.
12. Kwon, HM, Kim BJ, Lee S-H, Choi SH, Oh BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006; 37: 466-70.
13. Rundek T, White H, Boden-Albala B, Jin Z, Elkind M, Sacco RL. The metabolic syndrome and subclinical carotid atherosclerosis: the Northern Manhattan Study. J Cardiometab Syndr 2007; 2: 24-9.
14. Butler J, Mooyaart E, Dannemann N, Bamberg F, Shapiro M, Ferencik M, et al. Relation of the metabolic syndrome to quantity of coronary atherosclerotic plaque. Am J Cardiol 2008; 101; 8: 1127-30.
15. Najarian R, Sullivan L, Kannel W, Wilson P, D'Agostino R, Wolff P. Metabolic syndrome compared to type 2 diabetes mellitus as a risk factor for stroke. Arch Int Med 2006; 166: 2106-11.
16. McNeill A, Rosamond W, Girman C, Golden S, Schmidt MI, East H, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385-90.
17. Iglseder B, Cip P, Malaimare L, Ladurner G, Paulweber B. The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke 2005; 36: 1212-7.
18. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
19. Vilalta-Franch J, López-Pousa S, Garre-Olmo J, Turón-Estrada A, Pericot-Nierga I. Síndrome metabólico en la enfermedad de Alzheimer: influencias clínicas y evolutivas. Rev Neurol 2008; 46: 13-7.
20. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 1583-633.
21. Sacco RL. Secondary prevention after ischaemic stroke: risk factor management. In: Cerebrovascular diseases. American Academy of Neurology, 60th Annual Meeting. Chicago, 12-19 de abril de 2008.
22. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006; 83: 1248-51.
23. Arenillas JF, Moro MA, Davalos A. The metabolic syndrome and stroke: potential treatment approaches. Stroke 2007; 38: 2196-203.
24. Kurth T, Logroscino G. The metabolic syndrome. More than the sum of its components? Stroke 2008; 39: 1068-9.
25. Cooper-De Hoff RM, Pepine CJ. Metabolic syndrome and cardiovascular disease: challenges and opportunities. Clin Cardiol 2007; 30: 593-7.
26. Centers for Disease Control and Prevention. URL: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5536a1.htm?s-cid=mm5536a1-e. [26.10.2007].
27. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States,1999-2004. JAMA 2006; 295: 1549-55.
28. Farin HMF, Abbasi F, Reaven GM. Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in non diabetic adults. Am J Clin Nutr 2006; 83: 47-51.
29. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
30. Wing RR, Goldstein MG, Acton KJ, Birch LL, Jakicic JM Sallis JF Jr, et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior and physical activity. Diabetes Care 2001; 24: 117-23.
31. Adams K, Schatzkin A, Harris T, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-8.
32. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American College of Cardiology Foundation. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110: 2952-67.
33. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement of the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention; the American Academy of Neurology affirms the value of this guide. Stroke 2006; 37: 577-617.
34. Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001; 358: 1026-7.
35. Droste DW, Ritter MA, Dittrich R, Heidenreich S, Wichter T, Freund M, et al. Arterial hypertension and ischaemic stroke. Acta Neurol Scand 2003; 107: 241-51.
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
37. Nawrot T, Den Hond E, Thijs L, Staessen JA. Isolated systolic hypertension and the risk of cardiovascular disease. Curr Hypertension Rep 2003; 5: 372-9.
38. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: 85-151.
39. Hayes SN. Preventing cardiovascular disease in women. Am Fam Phys 2006; 74: 1331-40.
40. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al, HOPE investigators. Heart outcome prevention evaluation. Use of ramipril in preventing stroke: double blind randomized trial. BMJ 2002; 358: 1194-5.
41. Deveraux RB, Dahlöf B, Kjeldsen S, Julius S, Aurup P, Beevers G, et al, LIFE Study Group. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease, a substudy of the LIFE randomized trial. Ann Intern Med 2003; 139: 169-77.
42. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, et al. Writing Committee for the PROGRESS Collaborative Group. Effects of perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke 2004; 35: 116-21.
43. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 2741-8.
44. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
45. MacMahon S, Rodgers A, Neal B, Woodward M, Chalmers J. The lowering of blood pressure after stroke. Lancet 2002; 358: 1994-5.
46. Johnston SC, Nguyen-Huynh MN, Schwarz ME, Fuller K, Williams CE, Josephson SA, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol 2006; 60; 301-13.
47. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Pathwardan MB, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29.
48. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al, for the American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109: 672-93.
49. Iadecola C, Gorelick PB. Hypertension, angiotensin and stroke; beyond blood pressure. Stroke 2004; 35: 340-50.
50. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care 2003; 26 (Suppl 1): S25-7.
51. Nathan DM, Cleary PA, Backlund J Y, Genuth SM, Lachin JM, Orchard TJ, et al, for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
52. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
53. Schram MT, Van Ittersum FJ, Spoelstra-de Man A, Van Dijk RA, Schalkwick CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens 2005; 19: 429-37.
54. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004; 27: 978-83.
55. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006; 29 (Suppl 1): S4-42.
56. Sniderman AD, Lamarche B, Tilley J, Seccombe D, Frohlich J. Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care 2002; 25: 579-82.
57. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL). N Engl J Med 2006; 355: 549-59.
58. Castilla-Guerra L, Fernández-Moreno MC, López-Chozas JM, Jiménez-Hernández MD. Estatinas y enfermedad cerebrovascular: nuevas perspectivas en la prevención del ictus. Rev Neurol 2007; 44: 95-100.
59. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to date meta-analysis. Stroke 2004; 35: 2902-9.
60. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.
61. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-8.
62. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806-11.
63. Ovbiagele B, Saver JL, Lyn MJ, Chimowitz M. WASID Study Group. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology 2006; 66: 1344-9.
64. Lann D, Galagher E, Leroith D. Insulin resistance and the metabolic syndrome. Minerva Med 2008; 99: 253-62.
65. American Academy of Neurology 2008 clinical practice guidelines. URL: http:/www.aan.com. [10.09.2008].
66. Liechtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006. A scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114: 82-96.
67. Pearson TA, Bazzare TL, Daniels SR, Fair JM, Fortman SP, Franklin BA, et al. American Heart Association guide for improving cardiovascular health at community level: a statement of public health practitioners, healthcare, providers and health policy makers from the American Heart Association. Expert panel on populations and prevention science. Circulation 2003; 107: 645-51.
68. Endres M, Gertz K, Lindauer U, Katchanov J, Schultze J, Schrök H, et al. Mechanisms of stroke protection by physical activity. Ann Neurol 2003; 54: 582-90.
69. Gordon N, Gulanick M, Costa F, Fletcher G, Franklin BA, Roth EJ, et al. Physical activity and exercise recommendations for stroke survivors: an American Heart Association scientific statement from the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation and Prevention; the Council on CardiovascularNursing, the Council on Nutrition, Physical Activity and Metabolism; and the Stroke Council. Stroke 2004; 35: 1230-40.
70. Damlo S. American Heart Association publishes guidelines on CVD prevention in women. Am Fam Phys 2007; 75: 1089-92.
71. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. AHA statistical update; heart disease and stroke statistics (2008 update). Circulation 2008; 117: 25-146.
72. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
73. Adams HP, Del Zoppo GJ, Von Kummer R. General measures to prevent stroke. In Adams HP, Del Zoppo GJ, Von Kummer R, eds. Management of stroke: a practical guide for the prevention, evaluation and treatment of acute stroke. 3 ed. México DF: Professional Communications; 2006. p. 33-68.
74. Ceska R. Clinical implications of the metabolic syndrome. Diabetes Vasc Dis Res 2007; 4 (Suppl 3): S2-4.